Stock-Based Compensation

6 Months Ended

Jun. 30, 2011

STOCK-BASED COMPENSATION [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

STOCK-BASED COMPENSATION:

The Company’s net income (loss) for the six months ended June 30, 2011 and June 30, 2010 included $0.5 million and $1.2 million, respectively, of stock based compensation expense. Stock based compensation for the six months ended June 30, 2011 included $152,317 related to the accelerated vesting of certain stock options upon the acceptance by the FDA of the Company's preterm birth indication NDA in accordance with the original stock option agreements..

	Six Months Ended June 30,
Stock Based Compensation	2011		2010
Cost of revenues	$	6,618	$	37,831
Selling and distribution	—		326,782
General and administrative	454,855		777,610
Research and development	42,910		62,736
Total	$	504,383	$	1,204,959

During the six months ended June 30, 2011, the Company granted 1,035,000 options to employees. During the six months ended June 30, 2011, 515,050 options expired unexercised, most of which were out of the money options that had been granted to the previous sales and marketing organization.